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Abstract
TcTASV-C is a protein family of about 15 members that is expressed only in the trypomasti-
gote stage of Trypanosoma cruzi. We have previously shown that TcTASV-C is located at
the parasite surface and secreted to the medium. Here we report that the expression of dif-
ferent TcTASV-C genes occurs simultaneously at the trypomastigote stage and while some
secreted and parasite-associated products are found in both fractions, others are different.
Secreted TcTASV-C are mainly shedded through trypomastigote extracellular vesicles, of
which they are an abundant constituent, despite its scarce expression on culture-derived try-
pomastigotes. In contrast, TcTASV-C is highly expressed in bloodstream trypomastigotes;
its upregulation in bloodstream parasites was observed in different T. cruzi strains and was
specific for TcTASV-C, suggesting that some host-molecules trigger TcTASV-C expression.
TcTASV-C is also strongly secreted by bloodstream parasites. A DNA prime—protein boost
immunization scheme with TcTASV-C was only partially effective to control the infection in
mice challenged with a highly virulent T. cruzi strain. Vaccination triggered a strong humoral
response that delayed the appearance of bloodstream trypomastigotes at the early phase of
the infection. Linear epitopes recognized by vaccinated mice were mapped within the
TcTASV-C family motif, suggesting that blockade of secreted TcTASV-C impacts on the
settlement of infection. Furthermore, although experimental and naturally T. cruzi-infected
hosts did not react with antigens from extracellular vesicles, vaccinated and challenged
mice recognized not only TcTASV-C but also other vesicle-antigens. We hypothesize that
TcTASV-C is involved in the establishment of the initial T. cruzi infection in the mammalian
host. Altogether, these results point towards TcTASV-C as a novel secreted virulence factor
of T. cruzi trypomastigotes.
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Author summary
Trypanosoma cruzi is the kinetoplastid parasite that causes Chagas’ disease, a neglected
infection endemic in Latin America and emerging worldwide. Being vaccines currently
unavailable and treatments not completely effective, identification and characterization of
parasite molecules that can be target for these interventions are urgently needed. Of par-
ticular interest are surface anchored and secreted proteins involved in parasite—host
interplay. Recently, extracellular vesicles released from protozoan pathogens have been
shown to alter host cell function favoring the establishment of infection. Trypomastigotes
are the disseminating stage of T. cruzi, being their presence in peripheral blood a hallmark
of early acute infection in mammals. While the most abundant proteins of the trypomasti-
gote surface are fairly well characterized, little is known about other, less abundant and
more recently discovered multigenic families, which could have critical functions in the
parasite—host interaction. The T. cruzi Trypomastigote Alanine, Valine and Serine rich
proteins (TcTASV) belong to a medium-size multigene family of ~40 members that
remained unobserved until a few years ago when it was identified through a trypomasti-
gote-enriched cDNA library. Almost simultaneously, an expression library immunization
approach designed to discover novel vaccine antigens in T. cruzi, spotlighted the
TcTASV-C subfamily, as a fragment of a TcTASV-C gene was identified in a pool of pro-
tective clones. A distinctive feature that characterizes TcTASV proteins–and particularly
the TcTASV-C subfamily- is their predominant expression in trypomastigotes. Recent
transcriptomic and proteomic studies uphold our previous observations that the TcTASV
family is over-represented in the trypomastigote stage, and therefore could represent an
interesting target for rational intervention against T. cruzi infection. Here show that
TcTASV-C is mainly secreted through extracellular vesicles (EVs) of trypomastigotes, and
is a major cargo of its content. We have also shown that TcTASV-C is much more
expressed in trypomastigotes purified from blood from infected mice than in trypomasti-
gotes harvested from in vitro cultures, suggesting that host molecules should trigger
TcTASV-C expression in vivo during the infection. The immunization of mice with
TcTASV-C interfered with the early acute phase of T. cruzi infection through a strong
humoral immune response. TcTASV-C should be considered as a novel secreted virulence
factor of T. cruzi trypomastigotes and -although its biological function is still unknown-
we hypothesize its participation in the early steps of T cruzi infection in the mammalian
host.
Introduction
Trypanosoma cruzi, is the kinetoplastid pathogen that causes Chagas’ disease. There are about
10 million people currently infected and more than 50–60 million people living in endemic
areas, at risk of infection. Chagas’ disease is a chronic debilitating illness with symptoms gener-
ally appearing 10 or more years after the initial infection [1–3]. At this stage, anti-parasitic
drugs are poorly effective and patients are treated according to their cardiac, digestive or neu-
rological compromise [4–5]. Acute infection is usually undetected because of its mild and
unspecific symptoms and, therefore, the patients are not diagnosed. The acute phase of the
infection is characterized by the presence of high levels of trypomastigotes in blood. These
nonreplicative trypomastigotes invade nucleated cells, where they differentiate to the amasti-
gote stage that replicates in the cytoplasm and differentiates again to trypomastigotes. Then,
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the infected cell bursts and trypomastigotes are released once again to circulation. During the
acute phase this cycle repeats itself actively and the trypomastigote disseminates the infection
to several organs and tissues [6]. Considering the absence of preventive or chemoprophylactic
vaccines as well as the life cycle of the parasite, uncharacterized molecules differentially
expressed in the infective trypomastigote stage can be interesting novel targets for rational
intervention against Chagas’ disease [7,8].
The T. cruzi Trypomastigote Alanine, Valine and Serine (TcTASV) rich proteins belong to
a medium-size multigene family of ~40 members that was identified from a library of trypo-
mastigote-enriched mRNAs [9]. The TcTASV family is conserved among all the T. cruzi line-
ages analyzed so far and has no orthologues in other species, including the closely-related
trypanosomatids T. brucei, T. rangeli and Leishmania sp. [9]. TcTASV proteins, whose function
is still unknown, are expressed mainly in the trypomastigote stage. The N- and C-terminal
regions of the TcTASV proteins possess a signal peptide and a consensus for a GPI anchor
addition, respectively, and display the highest level of conservation, while the central region
presents more variability [9]. TcTASV family can be distinguished by the common amino acid
motif tasv_all that starts approximately at amino acid 42 (Vx1x2x3[CES]
x4x5TDGx6Lx7Wx8x9x10x11Ex12x13Wx14x15Cx16x17x18P). The TcTASV family is comprised of
4 subfamilies -TcTASV-A, B, C and W- defined by the primary amino acid sequence and
length of polypeptides. Further, each subfamily presents certain amino acids at the indetermi-
nate positions (x1, x2, etc) of the tasv_all motif. For example, subfamilies TcTASV-C and
TcTASV-A both have proline and glycine at positions X4 and X5, while TcTASV-B contains
serine and arginine, and TcTASV-W has alanine at X4 and glutamic acid at X5.
The TcTASV-C subfamily includes approximately 15 genes (small variations are found in
different strains) with protein products of 330–360 amino acids [9, 10]. A few years ago, in the
search for novel vaccine candidates by a genetic immunization approach, a fragment of a
TcTASV-C gene (TcCLB.511675.3; ID TritrypDB, [11]) was identified among a pool of anti-
gens that protected mice from a parasite challenge with a highly virulent T. cruzi strain [12]. In
a first characterization of the TcTASV-C subfamily we found that TcTASV-C is a thickly gly-
cosylated ~60 kDa polypeptide, expressed in trypomastigotes and absent in all other parasite
stages [10]. TcTASV-C presents a characteristic distribution pattern of scattered dots along the
parasite surface and flagellum, and is spontaneously secreted to the medium. While anti-
TcTASV-C antibodies are detected in about 30% of chronically-infected patients, the seroprev-
alence in reservoir dogs with active infection rises to 75% [10,13]. In the experimental murine
T. cruzi model, TcTASV-C specific antibodies can be detected early from the beginning of the
infection [10]. Although TcTASV-C proteins are not major components of the parasite in try-
pomastigotes derived from in vitro cultured cells [10], several TcTASV-C peptides have been
recently identified in secretomes of T. cruzi trypomastigotes [14–16]. Interestingly, TcTASV
peptides were found in the bloodstream trypomastigote proteome, but not in proteomes from
in vitro cultured cell derived trypomastigotes [17]. Also, a recent analysis of an overall tran-
scriptome of the host cell and T. cruzi during the course of infection confirmed that the
TcTASV family is extensively over represented in trypomastigotes, relative to all the other
stages of the parasite, and several TcTASVs mRNAs are among the most abundant in the try-
pomastigote stage [18]. After being unnoticed for several years, and in agreement with our pre-
vious reports, these findings also outpoint towards TcTASVs as potential virulence factors and
as interesting targets for study and rational intervention.
Here we present results leading to a deeper understanding of the TcTASV-C subfamily and
its performance as a vaccine antigen.
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Results
TcTASV-C motif discovery
First, a bioinformatic analysis was carried out to determine whether there was a common pat-
tern among all TcTASV-C members. A distinctive and conserved tasv_c motif of 50 amino
acids was identified in all TcTASV-C proteins (Fig 1). In most proteins, the tasv_c motif starts
at amino acid 42–43, including and expanding the previously reported tasv_all motif, common
for all TcTASV proteins irrespectively of their subfamily (asterisks in Fig 1). Only TcTASV-C
proteins are retrieved by searching any database with the tasv_c motif.
Several TcTASV-C genes are simultaneously expressed in the
trypomastigote stage
We have already described that TcTASV-C is expressed both at the parasite surface and
secreted to the medium [10]. To investigate whether–among the 15 TcTASV-C genes of CL
Brener strain- several genes (or only one) are simultaneously expressed, and to clarify if sur-
face-located and secreted TcTASV-C proteins are expressed from the same genes, we under-
took a 2D gel based approach (Fig 2). More than one TcTASV-C product was observed both
in the parasite-associated and in the secreted fractions (Fig 2), suggesting that more than one
TcTASV-C gene are simultaneously expressed. On the other hand, there were common and
differential TcTASV-C spots detected in both fractions. There was a clear band of higher
molecular weight only present in the parasite fraction (arrow in Fig 2, upper panel) and two
bands of more acidic isoelectric point (pI) in the secreted one (arrowheads in Fig 2, lower
panel). Two other bands seemed to be shared by both samples.
These results show that the expression of different TcTASV-C genes occurs simultaneously
at the trypomastigote stage and suggest that while some secreted and parasite-associated prod-
ucts are found in both fractions, others are different.
Most of the TcTASV-C produced by CL Brener trypomastigotes is secreted
through extracellular vesicles
TcTASV-C is secreted and also detected–by immunofluorescence microscopy- at trypomasti-
gote surface in spots that are compatible with detergent resistant domains [10]. These domains
are often associated with secretion of molecules through extracellular vesicles (EVs) [20,21]. In
this context, we investigated whether TcTASV-C proteins were released associated with EVs
or as soluble factors (VF: vesicle-free fraction). In a first set of experiments, trypomastigote-
derived conditioned media was resolved by ultracentrifugation in density gradients;
TcTASV-C was detected in fractions corresponding to extracellular vesicles (S1 Fig).
We next investigated whether TcTASV-C proteins were released associated with large (V2)
or small (V16) EVs, whose presence and purity was confirmed by transmission electron
microscopy (TEM; Fig 3A). All samples showed vesicles of 30–130 nm in size after 2 h of ultra-
centrifugation, while vesicles obtained after 16 h were smaller (~50 nm; Fig 3A). TcTASV-C
was secreted in both EVs populations in the CL Brener strain (Fig 3B); in the small EV fraction
(V16, Fig 3B, upper panel) TcTASV-C appeared as a highly abundant component, while it was
almost undetectable on parasite pellets at these conditions. This agrees with the already
reported low level of expression of TcTASV-C on parasite body in cell derived trypomastigotes
[10]. Longer exposure times were needed to evidence the TcTASV-C expression on trypomas-
tigotes but render overexposed and unclear images for V2 and V16 fractions. As expected, the
heat shock protein 70 (HSP70), a secretome marker, was detected in all fractions and, TcSR62,
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a nucleo-cytoplasmic and non-secreted RNA binding protein, only in the parasite pellet (Fig
3B) [10,22,23].
Fig 1. The tasv_c motif is distinctive for all TcTASV-C proteins. Graphical representations of patterns were generated after multiple sequence alignment of all
TcTASV-C protein sequences from different strains (n = 39; S1 Dataset) with WebLogo [19]. The tasv_c motif starts at amino acids 42–43 of most TcTASV-C proteins
and encompass 50 amino acids. Asterisks denote conserved amino acids of tasv_all motif.
https://doi.org/10.1371/journal.pntd.0006475.g001
Fig 2. Several TcTASV-C genes are simultaneously expressed at the surface of trypomastigotes and secreted to the
medium. CL Brener trypomastigotes were incubated for 2 h at 37˚C in serum-free medium; trypomastigotes (pellet,
upper panel) and secreted fraction (supernatant, bottom panel) were processed by 2D electrophoresis and analyzed by
western blot.
https://doi.org/10.1371/journal.pntd.0006475.g002
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A proteomic analysis of V2 and V16 secreted extracellular vesicles of CL Brener strain was
also carried out, to confirm our western blots results and, besides, because there are no proteo-
mic analysis of V2 and V16 cargo proteins of trypomastigotes. Indeed, the data currently avail-
able from exoproteomes of trypomastigotes were derived from total secreted material or from a
mixture of vesicles from parasites and host cells purified together [14–16]. High confidence pep-
tides of four TcTASV-C genes were found both in V2 and V16 samples (TcCLB.508741.440,
TcCLB.509123.10, TcCLB.509147.40, TcCLB.508737.10), which is in line with the 2D western
blot results. Although TcTASV-C peptides were detected in both EV fractions, is noteworthy
that each EV population presented a differential set of major proteins (V2: n = 271; V16:
n = 189), and only a minor core of 142 common proteins (among which are the TcTASV-C
peptides) (S2 Fig). This suggests that both fractions of vesicles correspond to different popula-
tions. Surface, intracellular as well as a considerable percentage of hypothetical proteins were
identified by proteomics in trypomastigote EVs (S2 Fig). In context, the picture obtained could
indicate that–at least at the assayed conditions- the paucity of TcTASV-C in the parasite’s body
probably reflects that most of TcTASV-C produced is delivered to the secretory pathway.
Secretion profile of TcTASV-C in other T. cruzi strains
We then analyzed the secretion profile of TcTASV-C in T. cruzi strains that encompass a wide
spectrum of virulence and also represented the major T. cruzi lineages [24]. Overall,
Fig 3. TcTASV-C is mostly secreted in EVs from trypomastigotes of CL Brener strain. (A) Representative TEMs of
large (V2) and small (V16) EVs. Vesicles are indicated by black bars and clusters formed by ultracentrifugation are
marked with black arrowheads. (B) 30x106 trypomastigotes and the secretion equivalent of small EVs (V16), large EVs
(V2) and EV-free fraction (VF) were processed by western blot with antisera against TcTASV-C, HSP70 and TcSR62.
https://doi.org/10.1371/journal.pntd.0006475.g003
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TcTASV-C was secreted in EVs in all the strains analyzed (Fig 4). Only mild differences in
TcTASV-C secretion profile were detected among strains. In the low-virulent SylvioX10 strain,
TcTASV-C seemed to be poorly represented in small (V16) EVs, while in 173 strain (DTU
TcI)–middle-virulence- the secretion profile of TcTASV-C was quite similar to that found in
CL Brener strain (Fig 3), which is also of intermediate virulence in the murine model. In cul-
ture-derived trypomastigotes from highly virulent strains (i.e. Y, TcII and RA, TcVI) a more
dynamic pattern of secretion was observed, and TcTASV-C was detected alternatively in dif-
ferent fractions (Fig 4 and S3 Fig). Particularly for the Y strain, trypomastigotes released on
the 1st day after cells began to lyse usually showed the profile depicted on Fig 4, while
TcTASV-C expression shifted to V16 and VF fractions, on EVs secreted from parasites har-
vested the 2nd and 3rd day, showing a dynamic expression pattern (S3 Fig). As a whole, in all
the analyzed strains, TcTASV-C was significantly more represented in the secreted than in the
parasite associated fraction. Of note, the total protein content secreted in EVs was similar for
all strains thus allowing to discard that changes in TcTASV-C expression by each parasite
strain had a correlation with the amount of total EVs secretion.
TcTASV-C expression and secretion in bloodstream-derived
trypomastigotes
Strikingly, the first proteomic evidences of TcTASV-C were registered few years ago with the
publication of the proteome of bloodstream trypomastigotes [17]. In contrast, no evidence of
expression of TcTASV-C was noticied when proteomics of culture-derived trypomastigotes
were analized. Therefore, we decided to investigate the TcTASV-C expression profile in blood-
stream trypomastigotes from different T. cruzi strains, in connection with its expression on
culture-derived trypomastigotes.
TcTASV-C was detected in 1x10^6 (or even less) bloodstream parasites (Fig 5A, upper
panel, BT lanes) while it was necessary to load more than tenfold of culture-derived trypomas-
tigotes to be weakly detected (Fig 5A, Cult lanes, upper panel). This finding was observed in all
T. cruzi strains assayed, belonging to different lineages, and proved that TcTASV-C is upregu-
lated in bloodstream forms. Importantly, this differential expression pattern between both
types of trypomastigotes was not observed with other proteins of T. cruzi, which were detected
accordingly to the parasite amount loaded on the gel (Fig 5A, middle and lower panels). As
well as detected for culture-derived trypomastigotes, bloodstream trypomastigotes were also
able to strongly secrete TcTASV-C. In the highly virulent RA strain (TcVI) TcTASV-C was
essentially identified in all secreted fractions, even from 1-2x10^6 trypomastigotes (Fig 5B and
S5 Fig).
TcTASV-C interacts with the surface of mammalian cells but does not
participate in parasite invasion in vitro
As molecules released by the parasite could potentially interact with host cells, we evaluated
this possibility for TcTASV-C on Vero (Fig 6A) and J774 (Fig 6B) cells. TcTASV-C (but not
the control protein GST) exhibited a dose-dependent adhesive capacity, suggesting a ligand-
receptor interaction. Similarly, EVs derived from trypomastigotes also interacted with mam-
malian cells (S4 Fig). This interaction was only observed with freshly isolated EVs, but not
with EVs that had been previously purified and stored at -80˚C. We also evaluated a potential
role of TcTASV-C on T. cruzi cell infection, employing as model two T. cruzi strains from dif-
ferent lineages and obtained from in vitro cultures (CL Brener, Fig 6C) or purified from blood
of infected mice (Tulahuen strain, expressing β-galactosidase, Fig 6D and 6E) [25,26]. Neither
pre-incubation of recombinant TcTASV-C with mammalian cells before infection (Fig 6C and
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6D) nor pre-incubation of trypomastigotes with anti-TcTASV-C sera (Fig 6E) interfered with
parasite internalization or cellular infection.
Delivery of antigens in EVs is a T. cruzi immune evasion strategy
The delivery of molecules in vesicles is a well known immune evasion mechanism exploited by
parasites [27]. We therefore investigated whether infected hosts could recognize the protein
content of secreted vesicles (Fig 7). Pooled sera from humans, mice or rabbits chronically
infected with T. cruzi failed to efficiently detect EVs antigens, although they strongly reacted
with trypomastigote antigens and with “naked” secreted proteins, both from RA and CL
Brener strains (Fig 7 and S6 Fig). These findings led us to hypothesize that immunization with
TcTASV-C–which is highly expressed in bloodstream trypomastigotes and also secreted-
would be a good target for immunotherapy control. This hypothesis was encouraged by our
previous finding of a TcTASV-C gene fragment among a pool of protective antigens [12].
Besides, being TcTASV-C expressed at early stages of the infection [10], we hypothesize that
humoral immune response could be mediating TcTASV-C neutralization.
TcTASV-C immunized animals presented a strong humoral response and a
partially delayed appearance of bloodstream trypomastigotes
To evaluate the performance of TcTASV-C as vaccine antigen, we designed a DNA-prime pro-
tein-boost schedule of immunization. The first 2 doses consisted of plasmid DNA of an
Fig 4. TcTASV-C is secreted in EVs in different T. cruzi strains. Purified EVs from SylvioX10 (TcI), 173 (TcI), Y (TcII), and RA (TcVI) strains were processed as
described in Fig 3. Tryp: trypomastigote; V2: large EVs; V16: small EVs; VF: vesicle-free fraction. The amount of proteins in EVs of different strains was similar, as
determined by micro-BCA assay. One representative of three independent experiment is shown.
https://doi.org/10.1371/journal.pntd.0006475.g004
Fig 5. TcTASV-C expression and secretion profile in bloodstream trypomastigotes A. Expression of TcTASV-C (upper panel), trans-sialidase (TS-SAPA,
middle panel) and HSP70 (lower panel) was analysed in trypomastigotes purified from blood (BT: bloodstream) along with in vitro cell-derived trypomastigotes
(Cult) from the same strains. Tulahuen (Tul; TcII), RA (TcVI), VD (TcVI), K98 strain (TcI). B. TcTASV-C expression on EVs (V2 and V16) and VF secreted
fraction from bloodstream trypomastigotes. Tryp: trypomastigote; V2: large EVs; V16: small EVs; VF: vesicle-free fraction.
https://doi.org/10.1371/journal.pntd.0006475.g005
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eukaryotic expression vector carrying a fragment of TcTASV-C [12] adjuvanted with a plas-
mid coding for GM-CSF [28]. In the 3rd and 4th doses, mice were boosted with TcTASV-C
recombinant proteins (two different genes fused to GST or histidine tags, rTcTASV-CGST and
rTcTASV-CHIS) adjuvanted with aluminium salts.
As expected, immunization was effective to induce high levels of total anti-TcTASV-C IgGs
(Fig 8). Most animals presented a mixed Th1/Th2 response, with strong IgG2a and IgG1
responses (Fig 8B and 8C). However, the cellular and cytokine response in splenocytes
obtained from mice 15 days after immunization, showed a low proliferative response and neg-
ligible levels of IFN-γ and IL-10 after rTcTASV-C restimulation in culture.
Two weeks after the last dose, animals were challenged with parasites of the highly virulent
RA strain (DTU TcVI). TcTASV-C vaccinated mice exhibited a delayed appearance of circu-
lating trypomastigotes and lower parasitemia peaks (Fig 9A–9C). Bloodstream trypomastigotes
were detected from the day 9th on, in all controls while were nearly unnoticeable until day 12th
in all TcTASV-C vaccinated (Fig 9A–9C). Besides, TcTASV-C vaccinated mice presented
reduced trypomastigote numbers at the peak of parasitemia (Fig 9C) and–overall- lower
Fig 6. TcTASV-C interacts with mammalian cells but not interfere with T. cruzi cellular infection. TcTASV-CGST (black squares) or GST (open circles) were
incubated with non-phagocytic professional cells (Vero cells) (A) or with professional phagocytic cells (J774) (B). Binding was assessed with a polyclonal anti-
TcTASV-CGST sera, in an ELISA-like assay. Values are means ± standard deviation of one assay (run by triplicate) that is representative of 3 independent experiments.
(p< 0.005 vs GST; Student’s t test). (C) Vero cells were pre-incubated with rTcTASV-C for 30 min and then infected with CL-Brener trypomastigotes O.N and
washed. After 48 hs cells were fixed and stained with May-Gru¨nwald Giemsa. Infected cells were enumerated by microscopy. (D) Cells were treated as in C, and
infected with purified bloodstream trypomastigotes (Tul-β-gal) for 18 hs. Then cells were washed and cultured for 72 h. β-galactosidase activity was measured with
CPRG, after cell lysis. (E) Alternatively, purified bloodstream trypomastigotes (Tul-β-gal) were pre-treated with anti TcTASV-C, anti-GST or sera from infected mice
for 30 min, before cell infection. Cell infection and measurements were as in D. Data were normalized to untreated control group, considered as 100% of infection.
https://doi.org/10.1371/journal.pntd.0006475.g006
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bloodstream parasite levels than the control group (Fig 9C; p<0.05, at 9 and 12 pdi, Mann-
Whitney test). Immunized mice also showed higher survival rates than controls (Fig 9D;
TcTASV-C, ~30%; control group, 0%; p<0.05 Log-Rank test). All animals that survived at the
end of experiments belonged to TcTASV-C vaccinated groups.
After T. cruzi challenge, vaccinated mice showed a strong response against parasite anti-
gens, with an IgG2a-biased isotype, similar to that found in infected animals (Fig 10A, 10B
and 10C). Besides, sera from vaccinated mice were able to lyse trypomastigotes in the presence
of an external complement source (Fig 10D); the lytic response was increased in mice after
infection. Focusing on the anti-EV response after T. cruzi challenge, vaccinated animals
reacted not only with TcTASV-C but also with other EV antigens, that were unseen by infected
but non-vaccinated animals (Fig 10E and 10F). Therefore, the vaccination was able to trigger
an EV-focused immune response after challenge that can’t be mimicked by unvaccinated
infected animals.
Fig 7. T. cruzi evades the immune system through the secretion of proteins into EVs. Western blot of CL Brener
EVs probed with sera from Infected mice, rabbits and humans. The reactivity of these sera against rTcTASV-C is
shown in the bottom panels. Tryp: trypomastigote; V2: large EVs; V16: small EVs; VF: vesicle-free fraction.
https://doi.org/10.1371/journal.pntd.0006475.g007
Fig 8. Anti-TcTASV-C antibody response in mice after vaccination. Serum samples were obtained before the first (Pre) and 15 days after the last dose (Post) of
immunization with TcTASV-C or Control schemes. (A) Total IgG, (B) IgG2a and (C) IgG1 responses against rTcTASV-CGST were determined by ELISA. Each dot
represents one individual animal. Absorbance against GST was subtracted. Dotted line indicates the cut-off (p< 0.005 vs control group, one-way ANOVA).
https://doi.org/10.1371/journal.pntd.0006475.g008
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Mapping of B-cell epitopes in TcTASV-C with sera from protected mice
As the main immune response detected in immunized animals was humoral, we mapped the
TcTASV-C epitopes detected. Peptides covering putative TcTASV-C epitopes were designed
by weighing linear B-cell epitope predictions (bioinformatic approach) and those epitopes pre-
viously discovered in a high-density peptide microarray screened with human sera [29]. We
selected 5 peptides of 15–20 amino acids to evaluate the reactivity of sera from TcTASV-C vac-
cinated, control and infected unvaccinated mice (Fig 11). Eighty-six percent (86%; 19/22) of
the sera from vaccinated mice reacted with at least one peptide, and 45% reacted with 2 or
more peptides (S1 Table). In contrast, only 30% (4/13) of sera from unvaccinated infected
mice (with previously reported reactivity against TcTASV-C) recognized any of these peptides
(S1 Table).
P46-62 and P172-189 were the peptides most detected by the sera from vaccinated group,
with 84% (16/19) of sera reacting with one or both of them (Fig 11 and S1 Table). P46-62 was
the peptide most detected by sera from vaccinated mice while it was not detected by any of the
sera from the infected group. Interestingly, P46-62 is part of the tasv_all motif, but is only par-
tially present in the rTcTASV-Cs employed in the vaccination schedule (TcTASV-CHIS:
Fig 9. Parasitological outcome of TcTASV-C vaccinated mice challenged with a virulent T. cruzi strain. Groups of mice (n = 5) were immunized
with TcTASV-C or vehicle (Control) and challenged with T. cruzi trypomastigotes of the RA strain (TcVI) 15 days after the last dose. Animals were
followed up for parasitemia and survival. Parasitemia of individual mice at 9 (A) and 12 (B) days post-infection. (C) Parasitemia during the course of
infection in TcTASV-C vaccinated and Control groups (p<0.05 and p<0.005 vs control; Mann-Whitney test). (D) Survival curve of challenged
TcTASV-C vaccinated and Control groups (p<0.05 vs Control group; Log-Rank test).
https://doi.org/10.1371/journal.pntd.0006475.g009
The TcTASV-C protein family is a novel virulence factor of trypomastigotes
PLOS Neglected Tropical Diseases | https://doi.org/10.1371/journal.pntd.0006475 May 4, 2018 11 / 26
Fig 10. Humoral anti-T. cruzi response after vaccination and after T. cruzi challenge. Serum samples were obtained before the first (Pre), 15 days after the last dose
(Post) of immunization and at 42 and 62 dpi. A pool of sera from chronically infected (non-vaccinated) mice was also evaluated (68 dpi infected mice, spontaneous
survivors from infection with 100 RA trypomastigotes by the intradermal plantar route). (A) Total IgG, (B) IgG2a and (C) IgG1 antibodies against total T. cruzi
antigens were determined by ELISA. Dotted line indicates the cut-off value. (D) Complement-mediated lysis of T. cruzi trypomastigotes. Parasites (500000/assay)
were incubated with inactivated sera from preimmune (Normal sera), GST-vaccinated (Control group), TcTASV-C vaccinated or vaccinated and surviving mice for 1
h at 37˚C, followed by treatment with fresh human complement (1:4) or inactivated human complement for an additional 1 h at 37˚C. Trypomastigote lysis was
calculated by counting living, motile and unstained parasites in a Neubauer chamber after staining with Trypan blue. Each dot represents 2–3 pooled sera, assayed
together. (E) and (F) Western blot of trypomastigote lysate (Tryp), EVs and EV-free supernatant fraction (VF) from CL-Brener (E) or RA (F). Proteins were probed
with immune sera from vaccinated mice (Post TcTASV-C vaccinated mice), sera from surviving vaccinated mice (62 dpi-TcTASV-C vaccinated mice) and RA-
infected (unvaccinated) mice (68 dpi-Infected mice). p<0.05 when pairwise compared to Control group by One-way ANOVA.
https://doi.org/10.1371/journal.pntd.0006475.g010
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KLSWRLRGEEEW; TcTASV-CGST: SWRLQGEEEW). Even more striking, the reactivity to
peptide P46-62 seems to be driven by the RLR triplet or the second arginine, since an identical
peptide with an unique substitution that changes the RLR motif to the RLQ, turned it into an
unrecognized peptide (P47-63; S1 Table). Both RLR and RLQ sequences are present in
TcTASV-C genes (see Fig 1), and represented by the rTcTASV-Cs employed in the vaccination
scheme (RLR in TcTASV-CHIS, RLQ in TcTASV-CGST).
Altogether these results support the idea that the broad anti-peptide reactivity of immu-
nized mice is probably mediating the partial resistance and/or the delay in the appearance of
circulating trypomastigotes in challenged mice.
Discussion
The T. cruzi TcTASV gene family remained unobserved until a few years ago when it was iden-
tified by our group through a trypomastigote-enriched cDNA library [9]. Almost simulta-
neously, an expression library immunization approach designed to discover novel vaccine
antigens in T. cruzi, spotlighted the TcTASV-C subfamily, because a fragment of a TcTASV-C
gene was identified in a pool of protective clones [12]. A distinctive feature that characterizes
TcTASV proteins–and particularly the TcTASV-C subfamily- is their predominant expression
in bloodstream trypomastigotes. Recent transcriptomic and proteomic studies uphold our pre-
vious observations that the TcTASV family is over-represented in the trypomastigote stage
[17,18], and therefore could represent an interesting target for rational intervention in T. cruzi
infection.
Here the TcTASV-C expression and secretion dynamics and its performance as an individ-
ual vaccine candidate were analyzed. We demonstrate that, despite its scarce expression on
culture-derived trypomastigotes, TcTASV-C is strongly secreted, and is a major component of
trypomastigote’s EVs, at least in the T. cruzi reference strain CL Brener. This was observed
both by western blot and proteomics on large (V2) and small (V16) EVs. It is a novelty,
although not unexpectedly, that a parasite-associated and low-expressed protein (or protein
family) is actually a highly abundant component of the trypomastigote secretome. The secre-
tion of EVs by parasites has been proposed as a pathogen-driven mechanism aimed to generate
-in the host- an environment that favours the initial infection [30–34]. Indeed, in most of the
Fig 11. B-cell epitopes detected in TcTASV-C by sera from vaccinated mice. Sera from vaccinated (uninfected,
n = 22) or infected (unvaccinated and TcTASV-C reactive, n = 13) mice recognized differential TcTASV-C peptides,
evaluated in an ELISA format. Reactivity is expressed as % of sera that were reactive for each peptide. All sera were
reactive against TcTASV-C proteins. Numbers in peptides indicate the amino acids of TcTASV-C encompassed by the
peptide (i.e. P46-62, P172-188).
https://doi.org/10.1371/journal.pntd.0006475.g011
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tested T. cruzi strains, TcTASV-C was mainly secreted contained into EVs. Of note, the more
virulent strains (i.e. RA and Y) presented also a more dynamic secretion pattern (Fig 4, Fig 5,
S3 Fig and S4 Fig). On the other hand, we have shown that TcTASV-C expression is upregu-
lated in bloodstream parasites, suggesting that some molecules present in the host trigger
TcTASV-C expression.
The potential of TcTASV-C as an individual vaccine candidate, however, was somehow
limited to the acute phase. In our model, TcTASV-C immunized mice achieved an enhanced
control of parasitemia at the beginning of the infection. The delayed appearance of blood-
stream trypomastigotes was along with the presence of functional antibodies in sera from
TcTASV-C vaccinated mice, with ability to lyse trypomastigotes by ADCC. This is also consis-
tent with the detection of TcTASV-C early upon infection and suggests that TcTASV-C could
have a role during this phase of infection [10,13] (unpublished results). We hypothesize that
the window of time with lower bloodstream parasites, gives a handicap to TcTASV-C primed
mice to launch effector mechanisms against the parasite. However, it has to be said, the
humoral response induced by vaccination was not strong enough to completely protect and
clear parasites from a lethal challenge, and mortality rates were only mildly improved. Like-
wise, Ramirez et al (2017) [35] have recently reported that EVs derived from the interaction
between mammalian cells and trypomastigotes potentiated parasitemia, particularly in the
early acute phase (3–6 days) of infection. This effect was stage-specific since it was not
observed with EVs derived from the interaction of mammalian cells with metacyclic trypomas-
tigotes or epimastigotes, suggesting that stage-specific EVs components might play a role in
survival and dissemination of this parasite stage in the vertebrate host [35].
Secretion of virulence factors contained in extracellular vesicles has also been understood as
a parasite strategy to deliver long distance effector molecules that should act in concert [36]. In
particular, T. cruzi trypomastigotes release EVs that can interact with the host and modulate
immune responses. The first communication in this way was in 2009, when Trocoli-Torrecil-
has et al [37] demonstrated that inoculation of mice with naked extracellular vesicles predis-
posed them to a more virulent infection, along with a strong inflammatory tissue damage and
higher parasitic loads in heart. In fact, the effect observed with whole EVs had been observed
several years before with an EV cargo molecule, the trans-sialidase (TS). Chuenkova and Per-
eira (1995) [38] reported that mice sensitized with TS were more susceptible to T. cruzi infec-
tion, displaying enhanced parasitemia and mortality. Here, by analyzing the proteome from
CL Brener EVs, we found peptides of both TS and TcTASV families, suggesting that both com-
ponents of trypomastigotes are secreted as part of the same cargo and can act in a concerted
fashion. Actually, in retrospective, we found several EV cargo proteins employed as vaccine
antigens with promising results [12,39–46]. Interestingly, peptides of most of these proteins
were found in our EV proteome (Tc24, SA85, CRP, MASP, TS, tryparedoxin-peroxidase, par-
aflagellar rod proteins, etc). We propose that immunization with some of the molecules deliv-
ered into EVs with proper adjuvanticity, could allow the host to develop an adequate immune
response against T. cruzi.
The prime and boost vaccination scheme employed here mostly triggered a humoral medi-
ated immune response able to block or neutralize surface anchored and/or secreted
TcTASV-C. Although yet unknown, we speculate that the possible function of the TcTASV-C
subfamily is exerted through its most conserved motif (tasv_c), which encompasses a 50 amino
acid long sequence at the amino terminus of the protein. Also, the shorter tasv_all motif com-
mon to all TcTASV subfamilies can be found within the tasv_c motif, but with specific amino
acids at certain positions for each subfamily (see Fig 1). Interestingly, a linear B-cell epitope
located within the tasv_all-tasv_c motif was exclusively recognized by sera from TcTASV-C
vaccinated mice (P46-62, Fig 11). This reactivity seems to be specifically prompted by the
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prime and boost vaccination scheme since sera from infected unvaccinated mice are unable to
react with this peptide, suggesting that antibodies against this motif are mediating the
TcTASV-C neutralization achieved–at least partially- by this vaccination scheme during the
early infection.
Packaging molecules into EVs can also be considered as a parasite driven strategy to escape
from the host immune surveillance or extracellular degradation until they reach the target cells
or tissues. In our hands, EV proteins contained in trypomastigote-secreted EVs were not
detected by sera from infected hosts from different species, in contrast with trypomastigote-
associated and freely secreted antigens, that were recognized by sera from infected hosts.
Indeed, this finding suggests that ~30% of sera from infected hosts that do recognize
TcTASV-C actually reacted against proteins attached to the parasite’s surface or freely-secreted
to the environment, but not against the TcTASV-C genes that are secreted contained into EVs.
We support the hypothesis that secretion of cargo in EVs (and particularly the secretion of
TcTASV-C) is another parasite-driven immune evasion mechanism. In a recently published
work, Bautista-Lopez et al (2017) [14] looked for “Trypomastigote Excreted Secreted Anti-
gens” (TESA, because the whole secreted population was analyzed) that are exposed to the
host immune system. They carried out an immune capture assay with T. cruzi-infected
patient’s antibodies to screen for novel and secreted antigens, which could be useful markers
of disease status. In accordance with our results, and although TcTASV-C peptides were found
in the TESA proteome, none of TcTASV proteins were revealed by patient’s sera. Altogether,
these results reinforce the idea that most of the proteins delivered into EVs are hidden from
the host or, at least, are hard to be detected in the way they are presented to the host immune
system.
In 2016, Queiroz et al [15] published the first proteomic analysis of the trypomastigote
secretome (which included both free and EV-secreted proteins) from the Y strain (DTU TcII),
and soon after Bautista Lopez et al (2017) [14] presented the proteome of EVs derived from
the culture of both cells and trypomastigotes (Tulahuen strain; DTU TcVI). In both of these
proteomes TcTASV peptides were eventually identified, supporting the results presented here
that demonstrated that, despite being a medium-size gene family, TcTASV proteins are an
important component of the trypomastigote secretome and EVs. Regarding the expression of
TcTASV-C in the trypomastigote EVs, it is notable that TcTASV-C is easily detected by west-
ern blot, suggesting it as a major EV component, especially in contrast with its weak expression
on parasite’s body of culture-derived trypomastigotes. Although TcTASV-C is hard to be
detected in culture-derived trypomastigote homogenates (undetectable for the conditions of
western blot in Fig 3B, upper panel), it is revealed as a major component of EVs in CL Brener
strain. In fact, the identification of peptides from 4 different TcTASV-C genes in our EV prote-
ome corresponds with this observation and also with the 2D gel results, where 4 spots were
detected as TcTASV-C proteins in the secreted fraction. The picture obtained for TcTASV-C
could indicate that the paucity of TcTASV-C in the parasite’s body probably reflects that most
of the protein produced is delivered to the secretory route, thus suggesting that its putative
function is related somehow to the development of a permissive environment for early T. cruzi
settlement. It is well known, but poorly documented, that parasites–and particularly T. cruzi
trypomastigotes- express a very different set of molecules when isolated from the host (i.e. in
vivo infection) than from culture (i.e. in vitro infection), basically in response to the pressure of
the immune system. Here, we demonstrate that TcTASV-C expression is much higher in
bloodstream than in culture-derived trypomastigotes. We show that this is true for different T.
cruzi strains and also that it is specific for TcTASV-C, but not for other antigens or virulence
factors of trypomastigotes. We still do not known what factors of the vertebrate host trigger
this expression, which is a matter of our current research. Besides, these results highlight the
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relevance of working with trypomastigotes obtained from in vivo sources to study the T. cruzi
biology, especially when research involves parasite stages that are under immune system pres-
sure in the vertebrate host.
The delivery of virulence factors in exosomes or extracellular vesicles is also a strategy to
interfere with host cell signaling pathways required to control infection. Exposure of mice to
exosomes of L. infantum resulted in higher parasitic loads in spleen, which was linked to a sup-
pressive T cell phenotype [30,31]. As well as Leishmania exosomes display immunomodulatory
properties, T. cruzi extracellular vesicles also do. In fact, Nogueira et al (2015) [47] found that
different T. cruzi strains secreted different concentration of vesicles. This variability could not
be associated with the current T. cruzi DTU classification because -for example- two TcI
strains presented polar secretion levels (Col vs. YuYu). Protein concentration and alpha-galac-
tosyl residues in secreted EVs also varied among the different strains, and without a lineage
specific association [47]. Focusing on the modulation of immune responses by EVs in the
acute phase of infection, only after stimulation with EVs from YuYu (DTU TcI) and CL-14
(DTU TcVI), peritoneal macrophages from C57BL/6 mice produced high levels of proinflam-
matory cytokines (TNF-alpha) and NO, via the TLR-2. This profile was not stimulated by EVs
from other T. cruzi strains. Similar findings were recently reported by Clemente et al (2017)
[48] employing EVs secreted by metacyclic trypomastigotes from other strains. In the present
work, we registered a variable expression of TcTASV-C in the different secretory fractions (i.e.
V2, V16 and soluble factors) among the different strains analyzed. Although we found similar
levels of total protein content in EVs derived from the different strains, it should be stated that
the protocols employed to isolate EVs and the strains analyzed were different. As in previous
works, we could not link a particular secretion profile with a certain T. cruzi DTU or strain.
This complex scenario led us to speculate that differences in EVs cargo could reflect the broad
spectrum of clinical manifestations observed in Chagas’ disease. Our opinion is that we are still
building a puzzle from somehow complementary but still fragmented data, showing currently
a complex and not very well understood picture.
In brief, we have demonstrated that TcTASV-C is a major component of bloodstream try-
pomastigotes, and that TcTASV-C is mainly secreted, either contained into EVs or free.
Besides, although with the prime and boost strategy employed TcTASV-C did not result a
promising vaccine candidate, it was possible to interfere with the early acute phase of T. cruzi
infection. Indeed, the strong anti-TcTASV-C humoral immune response elicited by immuni-
zations allowed to understand–partially- the TcTASV-C functionality; we hypothesize that
TcTASV-C is involved in the establishment of the initial T. cruzi infection in the mammalian
host. Although we highlight TcTASV-C as a potential antigen to bit the parasite in the early
acute phase, we bear in mind that an effective vaccine to control Chagas’ disease should
include other antigens and/or trigger also other arms of the host immune response. Ultimately,
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TcTASV-C recombinant proteins
TcTASV-CGST (amino acids 65 to 330 of ORF Tcruzi_1863-4-1211-93) was already cloned in
our laboratory in pGEX-3X and was expressed and purified as we previously described [10].
The same procedure was used with GST.
Amino acids 52 to 342 of the TcTASV-C gene AM492203 (GenBank; emb.CAM33606.1)
were cloned between BamHI and KpnI restriction sites, fused in the N-term to a Histidine tag
into pQE-30 (Qiagen). A point mutation was introduced to change the amino acid H56R.
TcTASV-CHIS was expressed and purified by standard methodologies for histidine-tagged pro-
teins (The QIAexpressionist). Purity of proteins was analyzed by SDS–PAGE, followed by
staining with Coomassie Brilliant Blue. Proteins were quantified (Bradford assay and/or Pico-
drop) and dialyzed against PBS. Recombinant proteins were stored aliquoted at −80˚C until
use.
For mice immunizations, purified recombinant proteins were incubated with a Polymyxin
B resin in a column format (Detoxy-Gel Endotoxin Removing Gel Thermo Scientific). Endo-
toxin levels were quantified by Amebocyte lysis assay (Limulus Amebocyte Lysate Test,
Lonza). Only preparations with endotoxin levels<100 U/mg were used.
Anti-TcTASV-C antisera
Recombinant TcTASV-CGST was digested with Factor Xa (GE Healthcare) and the purified
TcTASV-C fragment was used to produce specific anti-TcTASV-C sera in mice [49]. The spec-
ificity of the anti-TcTASV-C sera was verified by competition assays and western blot, both
against trypomastigotes lysates and recombinant proteins.
Recombinant TcTASV-CGST was used to produce complete anti-TcTASV-C-GST serum in
mice, following the same immunization protocol described above. The sera obtained reacted
both with TcTASV-C and GST.
Parasites and cell cultures
Vero and J774 cells were grown at 37˚C in a 5% CO2 humidified atmosphere in MEM or
RPMI (Gibco), respectively, supplemented with 10% fetal bovine serum (Natocor), 10 μg/mL
streptomycin (Sigma), 100 U/mL penicillin (Sigma).
Cell-derived T. cruzi trypomastigotes were cultured by passages in Vero cells at 37˚C and
5% CO2 humidified atmosphere in MEM (Gibco Life Technologies) supplemented with 10%
fetal bovine serum, 10 μg/mL streptomycin, 100 U/mL penicillin. Trypomastigotes were har-
vested from supernatants of infected cells as previously described [10]. As a rule, T. cruzi stocks
are kept in liquid nitrogen and all strains are regularly thawed twice a year to preserve their
biological characteristics. Parasites from Sylvio (TcI), 193–173 (TcI), K98 (TcI), Y (TcII), Tul
(TcVI), VD (TcVI), CL Brener (TcVI) and RA (TcVI) were employed [50–54].
Bloodstream trypomastigotes of the RA strain (DTU TcVI) were maintained in vivo by
weekly passages in CF1 mice with 105 trypomastigotes, at IMPaM (School of Medicine, Uni-
versity of Buenos Aires-CONICET) and at the BLS3 laboratory at UNSAM. The Tulahuen
strain expressing E. coli β-galactosidase (Tul-β-gal) was also maintained in vivo by passages on
CF1 mice at UNSAM [25]. Purification of bloodstream trypomastigotes was essentially carried
out by a Ficoll gradient with a swinging bucket rotor, essentially as previously described [55].
Bloodstream RA trypomastigotes used for EV purification, were either purified as stated above
or by swimming (2 x 40 min at 37˚C), essentially as described by Miranda et al (2015) [56].
Briefly, heparinized blood was diluted with 3 volumes of PBS and, after centrifuged at 300 x g
for 5 min, the sample was incubated for 40 min at 37˚C. The supernatant containing parasite
forms was then carefully harvested–to exclude the erythrocyte containing phase–and the
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procedure was repeated twice. Then, trypomastigotes were pelleted, washed with PBS-1% BSA,
resuspended in MEM and incubated for shedding assays, as described below. Similar volumes
of blood from non-infected mice were processed in parallel and used as controls.
Shedding assays and extracellular vesicles (EVs) isolation
Cell-derived trypomastigotes, were washed with MEM without serum and incubated at a con-
centration of 108 parasites/ml in MEM at 37˚C, during 6 hours, in a 5% CO2 humidified atmo-
sphere. Trypomastigote-secreted products (soluble plus vesicles) were isolated as previously
described [10]. A similar procedure was carried out for bloodstream trypomastigotes.
Extracellular vesicles were purified by an iodixanol density gradient (Optiprep, Sigma)
ultracentrifugation as described by van Deun J et al (2014) [57] or by sequential ultracentrifu-
gation as described by Bayer-Santos et al (2013) [22]. Briefly, for both procedures, after shed-
ding, parasites were removed by centrifugation and the cell-free supernatant filtered through a
0.45-μm syringe filter (Micron Separation Inc.).
A discontinuous gradient was created by layering 2,7 mL of 40%, 20%, 10% and 2,3 mL of
5% Optiprep solutions from bottom to top in a 13,2 mL polyallomer tube (Beckman Coulter).
The cell-free supernatant of trypomastigotes (EVs plus free secreted fraction, 2 ml) was over-
laid onto the top of the gradient, which was then centrifuged for 18 hours at 100,000 x g with-
out brake at 4˚C in a SW 41 Ti rotor in an Optima XL 100k ultracentrifuge (Beckman
Coulter). Gradient fractions of 1 mL were collected from the top of the gradient. Density was
determined weighing on an electronic balance a known volume of each fraction.
Alternatively, to isolate large and small extracellular vesicles, EVs plus the free secreted frac-
tion were centrifuged at 100.000 x g for 2 h at 4˚C to obtain the first pellet, enriched in large
extracellular vesicles (V2), and the resulting supernatant was centrifuged again at 100.000 x g
for 16 h at 4˚C, to obtain the second pellet, enriched in small extracellular vesicles (V16), and
the EV-free supernatant fraction (VF). All ultracentrifugation steps were carried out in a 70Ti
fixed angle rotor in an Optima XL 100k ultracentrifuge (Beckman Coulter).
All relevant methodological data of our EV’s isolation procedures have been submitted to
the EV-TRACK knowledgebase (EV-TRACK ID: EV170020) [58].
Electron microscopy
Extracellular vesicles were resuspended in Hepes Buffer, pH 6.5, and fixed with paraformalde-
hyde (4% in Hepes). Negative staining was carried out on grids coated with acrylic membranes
and graphene oxide. Extracellular vesicles were stained with 5 μl of 0.5% ammonium molyb-
date at pH 7.5, and observed using a Zeiss EM 109T transmission electron microscope operat-
ing at 80kV; the images were acquired with a Gatan ES1000W (11 Mpx) digital camera.
2D SDS-PAGE
For 2D gel electrophoresis, trypomastigotes were incubated in serum-free DMEM for 2 h a
37˚C (or at 0˚C for controls). The medium containing the secreted antigens and the parasites
were separated by centrifugation at 4000 x g for 10 min at 4˚C. Pelleted parasites were washed
twice in 10 mM Tris-Cl, pH 7.0, 25 mM sorbitol and, after being pelleted by centrifugation,
were lysed by vortexing for 30 s in 250 μl of IEF rehydration buffer (9M urea, 2M thiourea, 2%
CHAPS, 65 mM DTT, 0.5% IPG buffer [Amersham Pharmacia] and 0.002% bromophenol
blue) with protease inhibitor cocktail (Roche). The secreted material was also mixed with IEF
rehydration buffer and both the trypanosome lysate and the secreted antigens were incubated
at R.T for 1 h, with vortexing for 30 s every 15 min, as described by van Deursen et al (2003)
[59]. Samples were loaded into Immobiline DryStrip (pH 4–7, 13 cm; GE Healthcare) and
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isoelectric focusing carried out in an IPGphor Isoelectric focusing System for 24 h. Second-
dimension SDS-PAGE was carried out in a Hoeffer SE 600, and gels were transferred to nitro-
cellulose membranes in a semi-dry TE 70 PWR (Amersham Biosciences). Blocking and wash-
ing solutions and antibodies used were similar to those described below for conventional
western blot.
Extracellular vesicles (EVs) western blot
Thirty million (30x106) of in vitro cell-derived trypomastigotes, or its secretion equivalent
from small (V16), large (V2), total EVs or the soluble EV-free fraction (VF) were electropho-
resed on 10% denaturing polyacrylamide gels, and transferred to nitrocellulose membranes by
standard methodologies [60]. The correct transfer was verified by reversible membrane stain-
ing with Ponceau Red (5% w/v) in 1% (v/v) acetic acid. The membrane was blocked with PBS-
3% non-fat milk for 1 hour, washed with PBS-0.05% Tween and incubated with primary anti-
bodies. Anti TcTASV-C (mouse, 1/400), anti HSP-70 (rabbit, 1/1000) and anti-SR62 (rabbit,
1/1000) were employed. Then, washes were repeated and membranes were incubated with a
peroxidase-conjugated secondary antibody (anti-mouse or anti-rabbit, both from Thermo Sci-
entific) for 1 hour and the washes repeated. For the detection, we used a chemiluminescent
reagent (SuperSignal West Pico, or SuperSignal West Femto, Thermo Scientific). The emitted
signal was detected by exposure on radiographic plates (AGFA). For bloodstream trypomasti-
gotes, or its secretion equivalent from EVs, an additional blocking step with non-labelled anti-
mouse IgG (Sigma-Aldrich) before incubation with the primary antibodies was included.
Western blots were developed as indicated above or with Alexa Fluor 590 goat anti-mouse IgG
or Alexa Fluor 680 goat anti-rabbit IgG as secondary antibodies (Invitrogen) at a 1:20000 dilu-
tion and visualized with an Oddysey Infrared Imager (Li-Cor).
Proteomic analysis
Purified EVs (20 μg) were diluted in 50 mM ammonium carbonate. Mass spectrometry analy-
sis was carried out at Centro de Estudios Quı´micos y Biolo´gicos por Espectrometrı´a de Masa
(CEQUIBIEM), Argentina, in a Q Exactive HESI-Orbitrap coupled to a nano HPLC Easy-nLC
1000 (Thermo Scientific). MS/MS data were used to search the all the available Trypanosoma
cruzi databases at Tritrypdb (version 30) [11].
TcTASV-C- and EV- host cell interaction
Interaction assays were carried out by an ELISA-like assay, as described by Baida et al (2006)
[61]. Briefly, macrophage (J774) or epithelial (Vero) cells were cultured overnight, washed
with PBS-3% BSA and fixed with 1% paraformaldehyde in PBS for 15 minutes. The fixed cells
were blocked with PBS-3% BSA-1% normal goat serum for 1 hour at room temperature and
washed again. Recombinant proteins (TcTASVGST or GST) were incubated for 1 hour at 37˚C.
The cells were washed and then incubated for 1 hour at 37˚C with complete anti-TcTASVGST
sera, which recognizes both TcTASVGST and GST proteins. Normal mouse serum was used as
background control. Detection continued as for conventional ELISA technique. Three repli-
cates per condition and three independent tests were carried out. Data were analyzed by Stu-
dent t-test. A similar protocol was employed to assay the interaction EVs with Vero cells.
Briefly, cells were incubated with freshly isolated EVs for 1.5 h at 37˚C, washed and the interac-
tion detected by a pool of sera developed against soluble and membrane antigens of trypomas-
tigotes. Normal mouse sera and frozen EVs were used as controls.
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Interference of cell infection
The ability of rTcTASV-C to interfere with parasite infection on Vero cells was assessed in
vitro by two different methods and with two T. cruzi strains. In both set ups cells were incu-
bated with rTcTASV-C or GST (as a control), before infection. On one hand, 20000 Vero
cells/well were incubated in p24 Wells (Costar) for 24 hs at 37˚C. Then the cells were washed
and incubated with recombinant proteins (TcTASV-CGST or GST) in MEM 4% FBS at 37˚C
for 30 min. CL Brener trypomastigotes (10:1) were added to the cultures, and 18 h later unin-
ternalized parasites were washed and infection proceeded for additional 48 hs. Cells were then
fixed and stained with May-Gru¨nwald Giemsa. At least 500 cells were counted in each techni-
cal replicate, and the presence of amastigotes registered. Data were normalized to infected
(untreated) cells; 3 independent experiments were performed with 3 technical replicates each
one. On the other hand, T. cruzi bloodstream trypomastigotes (Tulahuen strain) expressing E.
coli β-galactosidase were used to infect treated Vero cells in p96 (Costar) in a relation of 10:1
[25,26]. After an overnight incubation (37˚C, 5% CO2), cells were washed with PBS to remove
non-infecting trypomastigotes and the culture maintained for additional 72 hs. Cells were then
lysed with Igepal (1% v/v) and β-galactosidase activity was spetrophotometrically measured
with the chromogenic substrate chlorophenol red β-D-galactopyranoside (CPRG). Reaction
was read at 595 nm in a multi-plaque reader FilterMax F5 (Molecular Devices).
Purified T. cruzi bloodstream trypomastigotes (Tul- β-gal) were pretreated for 30 min at
37˚C with anti-TcTASV-C sera (1/10) and then co-incubated (37˚C, 5% CO2, 18 h) with Vero
cells (ratio 10:1) in MEM–5% FBS in a 96-well plate format. Parasites pretreated with anti-GST
or normal sera were used as controls. Cell culture and quantification of infection were the
same as stated above. Untreated parasites were used to determine 100% of infection; 3 inde-
pendent experiments were performed with 3 technical replicates each one.
Plasmid DNA purification for immunization
For the preparation of plasmid DNA used in immunizations, E. coli DH5a containing a frag-
ment of the TcTASV-C gene TcCLB.511675.3 (amino acids 233 to 305) cloned in pCI_Not_32
[12] or the plasmid VR1019 that contains the murine GM-CSF gene [26] were first grown as
starter cultures in LB containing ampicillin at 37˚C for 8 hours, then inoculated into a larger
culture and grown O.N. and, finally, incubated additional 8 h in the presence of chlorampheni-
col (170 μg/ml) for amplification of plasmid copy number.
Plasmid DNA was purified with the QIAGEN EndoFree Plasmid Mega Kit (QIAGEN,
GmbH, Germany) according to manufacturer’s instructions. Purified DNA was resuspended
in TE endotoxin-free buffer and DNA concentration was estimated and stored at -20˚C. For
mice immunization, DNA was precipitated with ethanol and reconstituted at 1 μg/μl with ster-
ile endotoxin-free PBS. The VR1019_GM-CSF plasmid was gently provided by Dr. Walter R.
Weiss of the "Malaria Program and Pathology Division, Naval Medical Research Center,"
Maryland, United States.
Mice immunization, challenge and parasitological follow up
C3H/He mice (n = 10 per group) were vaccinated with a prime (plasmid DNA) and boost
(recombinant proteins) immunization protocol. Briefly, the first two doses consisted in intra-
muscular injections of plasmid DNA containing 100 μg of pCI_Not-TcTASV-C and 25 μg of
VR1019_GM-CSF [12, 28]. The third and fourth doses consisted in subcutaneous injections of
mixed TcTASV-CGST and TcTASV-CHIS (12.5 μg each one) with a colloidal suspension of alu-
minum hydroxide (Sigma). Control groups were immunized with 100 μg of the empty plasmid
backbone pCI_Not_32 plus 25 μg of VR1019_GM-CSF (doses 1 and 2) and 25 μg of GST
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along with aluminum hydroxide (doses 3 and 4). Fifteen days after the last dose, 3 mice per
group were sacrificed to evaluate cellular responses in spleen cells (cytokine production after
culture) and the remainder 7 mice challenged with 100 bloodstream trypomastigotes of the RA
strain by the intraperitoneal route [12]. Parasitemia was determined from day 7-on every 2–3
days until day 35. Mortality was daily monitored.
Immune responses in vaccinated mice
Spleens of immunized mice were aseptically removed and homogenized. Red blood cells were
lysed and cells cultured in RPMI 1640 supplemented with 2 mM L-glutamine, 100 U of penicil-
lin/ml, 50 μg of streptomycin/ml, and 10% FCS at a concentration of 4 × 106cells/ml in 24 well
plates (Nunc). Cells were stimulated with TcTASV-CGST, GST (10 μg/ml), anti-CD3 (0.2 μg/
ml) or solely maintained with culture medium (basal control) at 37˚C in a humidified atmo-
sphere of 5% CO2. After 72 h, supernatants were collected, and production of gamma inter-
feron (IFN-γ) and interleukin-10 (IL-10) was evaluated by sandwich ELISA according to
manufacturer’s instructions (BD OptEIA, Pharmingen, San Diego, CA).
Serology against recombinant antigens or whole T. cruzi trypomastigote lysates was deter-
mined by ELISA, as we previously described [10,12]. Mice were bled by submandibular punc-
ture to take serum samples 5 days before the immunization schedule start, 15 days after the last
dose and at 42–62 days post infection. ELISA plates were sensitized with 50 ng of recombinant
proteins or 100 ng of T. cruzi trypomastigote homogenates. Goat anti-mouse IgG, anti-IgG1
or anti-IgG2a conjugated to peroxidase (Thermo Fisher Scientific) were used as secondary
antibodies. Reaction was revealed with 3,3’,5,5’-Tetramethylbenzidine (Sigma) and H2O2 in
citrate buffer and read at 450 nm in a multi-plaque reader FilterMax F5 (Molecular Devices).
Antibody-dependent complement mediated lysis of trypomastigotes
Parasites (500000/assay) were incubated with inactivated sera (53˚C, 40 min) from vaccinated
or control mice, for 1 h at 37˚C, followed by treatment with fresh human sera (1:4) either with
active or inactivated complement for an additional 1 h at 37˚C [43]. Trypomastigote lysis was
calculated by counting living, motile and unstained parasites in a Neubauer chamber after
staining with Trypan blue.
Mapping of B-cell epitopes
Putative B-cell epitopes in TcTASV-C proteins were predicted by Bepipred software [62]. The
TcTASV-C epitopes identified in a previous work (peptide microarray screened with human
antibodies) were also considered [29]. Peptides were purchased from Genscript and screened
by ELISA. Briefly, plates were sensitized with 1 or 0.33 μg of peptide (for 96 or 384 plate for-
mat, respectively) in PBS O.N. Sera from vaccinated or infected mice were assayed at 1/100
dilution by triplicate. After incubation with a peroxidase- conjugated secondary antibody the
reaction was developed as described above. The cut off was set up for each peptide as the
media of the O.D. of the negative (uninfected unvaccinated) sera plus 3SD plus 10%. Reactivity
of an experimental serum was classified positive for an X peptide, if the ratio between its O.D.
for the peptide X and the cut-off value for peptide X, resulted in a value higher than 1 (i.e. O.D.
sera for peptide X/ cut-off peptide X>1).
Statistical analysis
For ELISA comparisons, we employed one-way ANOVA. Differences in the parasitemia
between groups were determined by the Mann–Whitney U test. In survival analysis, groups
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were compared by the Log-rank test. In all cases, Graph Pad Prism version 5.01 (GraphPad
Software, USA) was used and a P value below 0.05 was considered significant.
Supporting information
S1 Dataset. TcTASV-C protein sequences. TcTASV-C protein sequences retrieved from Tri-
TrypDB and Genbank and used to feed WebLogo.
(TXT)
S1 Fig. EVs from trypomastigotes were resolved by an Optiprep density gradient and ana-
lyzed by western blot. Gradient fractions were analyzed by Western blot using serum against
TcTASV-C, HSP70 and TS (SAPA).
(TIF)
S2 Fig. Proteomic analysis of EVs. (A) Genes identified in V2, V16 and both fractions. (B)
Genes were grouped according to their putative localization: intracellular, surface or hypothet-
ical proteins. (C) Surface and intracellular proteins presented according to their protein family
or function.
(TIF)
S3 Fig. TcTASV-C presents a dynamic pattern secretion on virulent strains. EVs purified
from Y strain (TcII) trypomastigotes collected in consecutive days (Day 1, Day 2 and Day 3)
from the same in vitro culture., were assayed for TcTASV-C expression. Tryp: trypomastigote;
V2: large EVs; V16: small EVs; VF: vesicle-free fraction.
(TIF)
S4 Fig. TcTASV-C secretion in bloodstream RA trypomastigotes. RA bloodstream trypo-
mastigotes were isolated from mice in the parasitemia peak and purified by swimming. Equal
volumes of blood from uninfected mice were processed in parallel, as control (Uninfected
blood line). EVs were obtained as described for Fig 6. RA Cult Tryp 30: 30x10^6 in vitro cell-
derived RA trypomastigotes; Tryp: trypomastigote; V2: large EVs; V16: small EVs; VF: vesicle-
free fraction. CL-Brener Cult Tryp 30 : 30x10^6 in vitro cell-derived CL-Brener trypomasti-
gotes; Uninfected blood: Normal mice blood processed like infected blood.
(TIF)
S5 Fig. Trypomastigote-derived EVs interact with mammalian cells. (A) Reactivity against
EVs of sera developed against T. cruzi membrane antigens (a-Tc membrane, left), anti-T. cruzi
soluble proteins (a-Tc soluble, center) and both sera pooled (right) against total EVs derived
from trypomastigotes. (B) Increasing amounts of EVs were incubated with to non-phagocytic
professional cells (Vero cells). Binding was determined by an Elisa-like assay with the “pooled
sera” shown in the right panel of A., followed by a colorimetric method. Values are
means ± standard deviation of triplicates. P < 0.01 compared with Frozen EVs values using
Student’s t test.
(TIF)
S6 Fig. Infected human sera reactivity against EVs from RA strain (TcVI). Western blot of
RA EVs purified with differential centrifugation. Infected sera human were used to analyse the
reactivity. Tryp: trypomastigote; V2: large EVs; V16: small EVs; VF: vesicle-free fraction.
(TIF)
S1 Table. Reactivity of individual sera against TcTASV-C peptides.
(XLSX)
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